We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
2 own
4 watching
Current Price
$2.87
$-0.54
(-15.84%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
220.45M
52-Week High
22.52
52-Week Low
2.81
Average Volume
1.72M
Dividend Yield
--
P/E Ratio
--
Market Capitalization220.45M
52-Week High22.52
52-Week Low2.81
Average Volume1.72M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Read More
News & Events about Stockal+Disclaimer.pdf.
Business Wire
9days ago
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ('Biocytogen', HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogens proprietary antibodies against three...
Business Wire
1month ago
ADC Therapeutics SA (NYSE: ADCT) today announced abstracts on several of its antibody drug conjugates (ADCs), including ZYNLONTA (loncastuximab tesirine-lpyl), camidanlumab tesirine (Cami) and ADCT-602, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, which will be...
Business Wire
2 months ago
ADC Therapeutics SA (NYSE: ADCT) and Swedish Orphan Biovitrum AB (Sobi) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending the marketing authorization of ZYNLONTA (loncastuximab tesirine) for the...
Business Wire
2 months ago
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of ADC Therapeutics SA (ADC or the Company) (NYSE: ADCT) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or...
Ticker Report
3 months ago
JPMorgan Chase Co. raised its position in shares of ADC Therapeutics SA (NYSE:ADCT Get Rating) by 6.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,414,630 shares of...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$2.87
$-0.54
(-15.84%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00